The CRASH trial: the first large-scale, randomised, controlled trial in head injury

AUTOR(ES)

Roberts, Ian

FONTE

BioMed Central

RESUMO

The global epidemic of head injuries is just beginning. Many are caused by road traffic crashes. It is estimated that, by 2020, road traffic crashes will have moved from its present position of ninth to third in the world disease burden ranking, as measured in disability adjusted life years. In developing countries, it will have moved to second. The Corticosteroid Randomisation After Significant Head Injury (CRASH) trial is a large-scale, randomised, controlled trial, among adults with head injury and impaired consciousness, of the effects of a short-term infusion of corticosteroids on death and on neurological disability. Following a successful pilot phase, which included over 1000 randomised participants, the main phase of the trial is now underway. Over the next 5 years, the trial aims to recruit a total of 20,000 patients. Such large numbers will only be possible if hundreds of doctors and nurses can collaborate in emergency departments all over the world. The trial is currently recruiting, and new collaborators are welcome to join the trial (see ).

Documentos Relacionados

• A large‐scale, multicentre, double‐blind trial of ursodeoxycholic acid in patients with chronic hepatitis C
• Large-scale, high-efficiency production of coffee somatic embryos
• Mining SAGE data allows large-scale, sensitive screening of antisense transcript expression
• Does routine follow up after head injury help? A randomised controlled trial.
• A large-scale, gene-driven mutagenesis approach for the functional analysis of the mouse genome